AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs. This builds on their successful partnership from March 2020, which included eight de novo programs and led to emergency use authorization for two COVID-19 antibody therapies. Under the new agreement, Lilly gains rights to develop and commercialize resulting therapeutic antibodies, while AbCellera receives an upfront payment, research payments, and potential milestone payments and royalties.
AbCellera's CEO, Carl Hansen, expressed excitement about deepening their partnership with Lilly, aiming to increase their impact on patients across multiple therapeutic areas. The expansion demonstrates the success of their initial collaboration and AbCellera's capabilities in antibody discovery and development.
AbCellera (Nasdaq: ABCL) ha ampliato la sua collaborazione con Eli Lilly per sviluppare farmaci anticorpali per l'immunologia, le malattie cardiovascolari e i programmi di neuroscienze. Questo consolidamento si basa sulla loro partnership di successo del marzo 2020, che includeva otto programmi de novo e ha portato all'autorizzazione per uso emergenziale di due terapie anticorpali per il COVID-19. Con il nuovo accordo, Lilly ottiene i diritti per sviluppare e commercializzare gli anticorpi terapeutici risultanti, mentre AbCellera riceve un pagamento anticipato, pagamenti per la ricerca e potenziali pagamenti per traguardi e royalties.
Il CEO di AbCellera, Carl Hansen, ha espresso entusiasmo per il rafforzamento della loro partnership con Lilly, puntando ad aumentare il loro impatto sui pazienti in diverse aree terapeutiche. L'espansione dimostra il successo della loro collaborazione iniziale e le capacità di AbCellera nella scoperta e nello sviluppo di anticorpi.
AbCellera (Nasdaq: ABCL) ha ampliado su colaboración con Eli Lilly para desarrollar medicamentos de anticuerpos para programas de inmunología, enfermedades cardiovasculares y neurociencia. Esto se basa en su exitosa asociación de marzo de 2020, que incluía ocho programas de novo y condujo a la autorización de uso de emergencia para dos terapias de anticuerpos para COVID-19. Bajo el nuevo acuerdo, Lilly obtiene los derechos para desarrollar y comercializar los anticuerpos terapéuticos resultantes, mientras que AbCellera recibe un pago inicial, pagos por investigación, y posibles pagos por hitos y regalías.
El CEO de AbCellera, Carl Hansen, expresó su entusiasmo por profundizar su asociación con Lilly, con el objetivo de aumentar su impacto en los pacientes en múltiples áreas terapéuticas. La expansión demuestra el éxito de su colaboración inicial y las capacidades de AbCellera en el descubrimiento y desarrollo de anticuerpos.
AbCellera (나스닥: ABCL)는 Eli Lilly와의 협력을 확장하여 면역학, 심혈관 질환 및 신경 과학 프로그램을 위한 항체 의약품 개발에 나섰습니다. 이는 2020년 3월의 성공적인 파트너십을 기반으로 하며, 여기에는 여덟 개의 새 프로그램이 포함되어 있었고, 두 개의 COVID-19 항체 치료제에 대한 긴급 사용 승인으로 이어졌습니다. 새로운 계약에 따라 Lilly는 الناتج 항체의 개발 및 상업화 권리를 보유하며 AbCellera는 초기 지불금, 연구 지불금 및 잠재적인 이정표 지불금과 로열티를 받습니다.
AbCellera의 CEO인 Carl Hansen은 Lilly와의 파트너십을 심화하게 되어 기쁘며, 다양한 치료 영역에서 환자에게 미치는 영향을 증가시키는 것을 목표로 하고 있다고 밝혔습니다. 이번 확장은 초기 협력의 성공을 보여주며 AbCellera의 항체 발견 및 개발 능력을 입증합니다.
AbCellera (Nasdaq: ABCL) a élargi sa collaboration avec Eli Lilly pour développer des médicaments anticorps pour des programmes en immunologie, en maladies cardiovasculaires et en neurosciences. Cela s'inscrit dans le cadre de leur partenariat réussi de mars 2020, qui comprenait huit programmes de novo et a conduit à une autorisation d'utilisation d'urgence pour deux thérapies anticorps contre la COVID-19. Dans le cadre de ce nouvel accord, Lilly obtient les droits de développer et de commercialiser les anticorps thérapeutiques résultants, tandis qu'AbCellera reçoit un paiement initial, des paiements de recherche et des paiements de jalons potentiels ainsi que des redevances.
Le PDG d'AbCellera, Carl Hansen, a exprimé son enthousiasme quant à l'approfondissement de leur partenariat avec Lilly, visant à accroître leur impact sur les patients dans plusieurs domaines thérapeutiques. Cette expansion démontre le succès de leur collaboration initiale et les capacités d'AbCellera en matière de découverte et de développement d'anticorps.
AbCellera (Nasdaq: ABCL) hat seine Zusammenarbeit mit Eli Lilly erweitert, um Antikörpermedikamente für Immunologie, Herz-Kreislauf-Erkrankungen und Neurowissenschaftsprogramme zu entwickeln. Dies baut auf ihrer erfolgreichen Partnerschaft aus dem März 2020 auf, die acht de novo Programme umfasste und zu einer Notfallzulassung für zwei COVID-19-Antikörpertherapien führte. Nach dem neuen Vertrag erhält Lilly die Rechte zur Entwicklung und Vermarktung der resultierenden therapeutischen Antikörper, während AbCellera eine Vorauszahlung, Forschungszahlungen sowie potenzielle Meilensteinzahlungen und Lizenzgebühren erhält.
Der CEO von AbCellera, Carl Hansen, äußerte sich begeistert über die Vertiefung ihrer Partnerschaft mit Lilly, mit dem Ziel, ihre Wirkung auf Patienten in mehreren therapeutischen Bereichen zu erhöhen. Die Erweiterung zeigt den Erfolg ihrer ursprünglichen Zusammenarbeit und AbCelleras Fähigkeiten in der Antikörperentdeckung und -entwicklung.
- Expansion of collaboration with Eli Lilly, a major pharmaceutical company
- Successful advancement of all eight programs under the original agreement
- Emergency use authorization obtained for two COVID-19 antibody therapies
- Potential for increased revenue through upfront payment, research payments, milestone payments, and royalties
- Expanded therapeutic areas: immunology, cardiovascular disease, and neuroscience
- None.
Insights
The expanded collaboration between AbCellera and Eli Lilly marks a significant development in the biopharmaceutical industry. This partnership extension demonstrates the success of their previous ventures, particularly in developing COVID-19 antibody therapies and signals confidence in AbCellera's antibody discovery platform.
The expansion into immunology, cardiovascular disease and neuroscience is strategically important. These therapeutic areas represent large, growing markets with significant unmet medical needs. For AbCellera, this diversification reduces risk and potentially opens up new revenue streams. For Lilly, it leverages AbCellera's expertise to bolster its pipeline in key therapeutic areas.
Financially, this deal structure is favorable for AbCellera. The
Investors should note that while this expansion is promising, drug development is inherently risky and time-consuming. The success of this collaboration will ultimately depend on the clinical outcomes of the antibodies developed. However, the track record of their COVID-19 antibody program provides a strong foundation for optimism.
This expanded collaboration represents a significant business development for AbCellera, potentially impacting its long-term financial outlook. The deal structure, combining upfront payments, research funding, milestones and royalties, provides AbCellera with a balanced mix of near-term cash flow and long-term upside potential.
While specific financial terms weren't disclosed, deals of this nature in the biotech industry can be substantial. The expanded scope covering multiple therapeutic areas suggests a sizeable commitment from Lilly. For context, AbCellera's revenue for 2022 was
Investors should consider the following financial implications:
- Diversified revenue streams: Reduced reliance on COVID-19 antibodies
- Improved cash position: Upfront payment strengthens balance sheet
- Long-term growth potential: Milestone payments and royalties offer future upside
- R&D efficiency: Lilly funding research activities reduces AbCellera's burn rate
While the immediate financial impact may be modest, this deal enhances AbCellera's long-term prospects and validates its technology platform, which could positively influence investor sentiment and potentially the stock price.
This expanded collaboration between AbCellera and Eli Lilly is a testament to the growing importance of AI-driven antibody discovery in the pharmaceutical industry. It's particularly noteworthy that Lilly, a traditional pharmaceutical giant, is deepening its ties with a biotech company specializing in AI-powered drug discovery.
The expansion into immunology, cardiovascular disease and neuroscience is strategically sound. These are areas where biologics, particularly monoclonal antibodies, have shown great promise. For instance:
- Immunology: Antibodies like Humira and Keytruda have revolutionized treatment in autoimmune diseases and cancer
- Cardiovascular: Antibodies targeting PCSK9 have shown efficacy in lowering cholesterol
- Neuroscience: Antibodies are being explored for conditions like Alzheimer's and Parkinson's
This collaboration model, where a tech-driven biotech company pairs with a pharmaceutical company with deep clinical development and commercialization expertise, is becoming increasingly common. It allows each party to focus on its strengths while sharing in the potential upside.
The success of their COVID-19 antibody program, resulting in emergency use authorizations, likely played a important role in Lilly's decision to expand the collaboration. This track record of translating discoveries into approved therapies sets AbCellera apart in the competitive antibody discovery space.
For the broader pharmaceutical industry, this deal underscores the growing importance of AI and machine learning in drug discovery, potentially accelerating timelines and improving success rates in the notoriously lengthy and risky drug development process.
AbCellera has advanced all eight programs under the original agreement, and the licensed program resulted in emergency use authorization by the
“Lilly has been a terrific partner and is one of the most admired and innovative pharmaceutical companies in the world," said Carl Hansen, Ph.D., founder and CEO of AbCellera. “We are excited to deepen our partnership and potentially increase our impact on patients across multiple therapeutic areas.”
Under the expanded agreement, Lilly has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera has received an upfront payment, will receive research payments, and is eligible to receive downstream milestone payments and royalties on net product sales.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731236547/en/
Inquiries
Media: Kathleen Reid; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116
Source: AbCellera Biologics Inc.
FAQ
What new therapeutic areas are included in AbCellera's expanded collaboration with Lilly?
How many programs were included in AbCellera's original 2020 agreement with Lilly?
What was the outcome of AbCellera's COVID-19 antibody program with Lilly?
What financial terms are included in AbCellera's expanded agreement with Lilly?
